Abstract
OBJECTIVE: One of the most fre-quent types of primary liver cancer is hepatocel-lular carcinoma (HCC). Due to the high incidence of hepatitis B infection, HCC accounts for about 5% of all cancers. HCC is indeed one of the larg-est leading causes of cancer deaths in the world and the third biggest cause of cancer-related death. The purpose of our research was to see how effective TACE (Trans-Arterial Chemoem-bolization) therapy was in those who had hepa-tocellular cancer.MATERIALS AND METHODS: The Preferred Reporting Items for Systematic Reviews (PRIS-MA) statement was used to conduct the system-ic review. From their inception through the first week of January 2022, the following electronic da-tabases were thoroughly searched: PubMed, Em -base, PsycINFO, and the Cochrane Library, with no language constraints. The search terms were "transarterial chemoembolization " or "chemoem-bolization " or "TACE " AND "hepatocellular carci-noma " or "hematoma " or "HCC " or "liver cancer " or "liver tumor " AND "sorafenib ". The references of the discovered articles were also examined. The search included English papers with adult patients only.RESULTS: A total of 1,234 studies were found for screening after searching the literature in mul-tiple databases. 767 papers were removed based on titles and abstracts, but the complete text of the remaining 129 publications was full text and eligible. In total, 13 studies were included in this research. The study's screening flowchart was depicted using the PRISMA technique. The ma-jority of the findings was of a small magnitude. Even with chronic liver disease and huge tumor groupings, they agreed on the safety and efficacy of such multiple closures prior to plan resection (50 mm). Even after curative resection, the prog-nosis for these patients remains poor because of portal vein thrombosis, high frequency of liver failure, and microscopic tumor thrombosis.CONCLUSIONS: TACE is a low-cost palliative treatment for HCC. The initial tumor size is an in-dependent predictor of survival.